Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.63% | -94.36% | |||
| Depreciation & Amortization | 0.00% | -1.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2,082.35% | -99.48% | |||
| Operating Income | -2,082.35% | 99.48% | |||
| Income Before Tax | -26.14% | 73.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.14% | 73.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.14% | 73.79% | |||
| EBIT | -2,082.35% | 99.48% | |||
| EBITDA | -472.00% | 102.35% | |||
| EPS Basic | -30.00% | 76.19% | |||
| Normalized Basic EPS | 0.00% | 73.08% | |||
| EPS Diluted | -30.00% | 77.78% | |||
| Normalized Diluted EPS | 0.00% | 73.08% | |||
| Average Basic Shares Outstanding | 3.74% | 5.77% | |||
| Average Diluted Shares Outstanding | 3.74% | 5.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
